Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis

J Microbiol Immunol Infect. 2013 Feb;46(1):65-7. doi: 10.1016/j.jmii.2011.12.020. Epub 2012 May 22.


The B-cell depletion agent rituximab (RTX) is used in lymphoma and rheumatoid arthritis (RA), and there have been several case reports of an RTX-induced reactivation of hepatitis C virus in patients with lymphoma. However, there have been no papers detailing hepatitis C virus reactivation after RTX therapy in a patient with RA. Here we report a case of RTX-induced hepatitis C virus reactivation in a patient with RA. Physicians should be aware that a close follow-up of liver function and viral load is mandatory after RTX therapy in patients with RA and concomitant hepatitis C.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / adverse effects*
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy*
  • Female
  • Hepacivirus / pathogenicity*
  • Hepacivirus / physiology
  • Hepatitis C / chemically induced*
  • Hepatitis C / immunology
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects*
  • Middle Aged
  • Rituximab
  • Virus Activation*


  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab